Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Insomnia Clear all
Recruiting Phase 4 Interventional

The Role of mGluR5 in CBT-I

NCT07076342
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Cognitive Behavioral Therapy for Insomnia, PET Scan with [11C]ABP688
Behavioral · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Recruiting Not applicable Interventional

Comparing Acoustic Resonance Therapy (ART) vs. Cognitive Behavioral Therapy for Insomnia (CBT-I)

NCT07486882
View directory record Official record
Conditions
Chronic Insomnia Disorder
Interventions
Mayo Clinic Cognitive Behavioral Therapy for Insomnia (CBT-I), Acoustic Resonance Therapy (ART)
Behavioral · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Recruiting Phase 2 Interventional

Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease

NCT04436081
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Major Neurocognitive Disorder With Aggressive Behavior
Interventions
THC-free CBD Oil, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
50 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 19, 2026, 8:02 AM EDT
Withdrawn Not applicable Interventional

Auditory Stimulation for Insomnia and Depression

NCT07553364
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Insomnia
Interventions
Alpha phase-locked auditory stimulation, Sham Stimulation
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
20 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional

A Study of Eszopiclone in Subjects With Insomnia Related to Major Depressive Disorder

NCT00368030
View directory record Official record
Conditions
Insomnia, Depressive Disorder, Major
Interventions
Eszopiclone, Placebo
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
21 Years to 64 Years
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
65
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 19, 2026, 8:02 AM EDT
Not listed Phase 4 Interventional

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

NCT02669030
View directory record Official record
Conditions
Depression, Major Depressive Disorder, MDD, Insomnia
Interventions
suvorexant, Placebo
Drug
Lead sponsor
Institute for Advanced Medical Research, Alpharetta, GA
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy for the Treatment of Depression-Related Insomnia

NCT00255905
View directory record Official record
Conditions
Depression
Interventions
Cognitive behavioral therapy (CBT) for insomnia, Clinician monitoring
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
25 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2013 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Sounds for Sleep Study in Patients Suffering From Moderate to Severe Insomnia

NCT06021795
View directory record Official record
Conditions
Insomnia
Interventions
Sound Treatment
Device
Lead sponsor
Third Wave Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 19, 2026, 8:02 AM EDT
Not yet recruiting Not applicable Interventional

Deaf CBT-TS to Reduce Suicide Risk

NCT07279363
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Anxiety, PTSD - Post Traumatic Stress Disorder, Insomnia, Alcohol Use Disorder (AUD), Suicide Ideation
Interventions
Deaf CBT-TS
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Terminated Phase 4 Interventional Results available

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

NCT04195958
View directory record Official record
Conditions
Moderate-to-severe Allergic Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Rolling Hills Estates, California • Denver, Colorado • Pembroke Pines, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy for Insomnia with RTMS

NCT04258618
View directory record Official record
Conditions
Depression, Insomnia
Interventions
CBT-I (Cognitive Behavioral Therapy for Insomnia) with rTMS, Repetitive Transcranial Magnetic Stimulation
Behavioral · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 19, 2026, 8:02 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Mainstream Sleep Tracking Devices vs Polysomnography

NCT02744235
View directory record Official record
Conditions
Severe Sleep Apnea, Severe Insomnia, Epileptiform Activity
Interventions
Polysomnography Data, Jawbone UP®, Fitbit Charge ®
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 19, 2026, 8:02 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Terminated Phase 3 Interventional Results available

Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon

NCT00642694
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
Escitalopram, Ramelteon, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 19, 2026, 8:02 AM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

NCT04513912
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Matching placebo to Seltorexant, Quetiapine XR, Matching placebo to Quetiapine XR
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
75
States / cities
Birmingham, Alabama • Tucson, Arizona • Culver City, California + 62 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 19, 2026, 8:02 AM EDT
Not listed Phase 4 Interventional

Brain Mechanisms and Targeting Insomnia in Major Depression

NCT00628914
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
escitalopram and eszopiclone, Escitalopram, eszopiclone, and placebo, Escitalopram
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2010 · Synced Oct 19, 2026, 8:02 AM EDT
Recruiting Not applicable Interventional

IMST for Dementia Risk Reduction

NCT07349706
View directory record Official record
Conditions
Systolic Blood Pressure, Blood Pressure, Depression - Major Depressive Disorder, Anxiety, Sleep Quality, Physical Function, Cognitive Function
Interventions
Inspiratory Muscle Strength Training High-Resistance, Inspiratory Muscle Strength Training Low-Resistance
Device
Lead sponsor
Florida State University
Other
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

NCT03771664
View directory record Official record
Conditions
Major Depressive Disorder, Insomnia
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 19, 2026, 8:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiologic Correlates of Hypersomnia

NCT01719315
View directory record Official record
Conditions
Major Depressive Disorder, Primary Hypersomnia, Bipolar Disorder, Narcolepsy, Primary Insomnia
Interventions
Acoustical slow wave induction
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 19, 2026, 8:02 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Neurobiological Effects of Light on MDD

NCT02940769
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
light glasses, sham glasses (placebo)
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

NCT04533529
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Anaheim, California • Cerritos, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Not listed No phase listed Observational

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

NCT06539169
View directory record Official record
Conditions
Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis, Creutzfeld-Jakob Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Early-Onset Alzheimer Disease, Ehlers-Danlos Syndrome, Huntington Disease, Gaucher Disease, GM1 Gangliosidosis, Myasthenia Gravis, Pompe Disease, Sickle Cell Disease, Transthyretin Amyloid Cardiomyopathy, Rare Diseases
Interventions
Not listed
Lead sponsor
xCures
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Los Altos, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

NCT00511810
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose Fish Oil, High Dose Fish Oil
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 19, 2026, 8:02 AM EDT